Peptonic Medical AB granted patent in Europe for relief of provoked vulvodynia in women. Product ready for launch.
Peptonic Medical AB (publ) ("Peptonic") announces that the European Patent Office ("EPO") has granted a patent for the relief of provoked vulvodynia (previously referred to as vestibulitis), effective until April 2041. VagiVital Intimate Calming Gel, the company's proprietary product designed to alleviate the discomfort associated with vulvodynia, will be launched later this year. The product will also be introduced to existing and new international partners for broad distribution.
VagiVital Intimate Calming Gel provides immediate soothing and moisturizing effects for vulvodynia and relieves symptoms such as dryness, irritation, and itching. The product is based on the company's clinically proven gel formulation and is intended for use on the external genital area.
Vulvodynia is a condition characterized by pain around the vaginal opening. The burden of the condition in a woman’s life can be devastating, affecting sexual relationships daily activities, overall well-being, and quality of life. The prevalence of vestibulitis varies between studies but indicates that it affects one to two out of ten women aged 18 to 29. VagiVital Intimate Calming Gel is a valuable addition to Peptonic's existing portfolio of clinically proven self-care products for intimate medical conditions.
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic
Peptonic Medical AB (publ) is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and self-diagnostic tests in intimate women's health. The portfolio is sold under the brands Vagivital and Vernivia.
The company's vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively. Intimate health shall be natural, safe, and easy for women to manage on their own.
Central to Peptonic's growth strategy is the geographical expansion of VagiVital and Vernivia through local partners. Peptonic Medical also intends to continuously broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company's shares have been listed on the Spotlight Stock Market since 2014